Skip to NavigationSkip to content

Scottish Medicines Consortium

Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes

Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with the authorisation of four key therapies for NHS patients in Scotland.

Shionogi's Mulpleo recommended for NHS use across England, Wales and Scotland for chronic liver disease

Both the regulators governing NHS use of medicines in England, Wales and Scotland – the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) – have moved to recommend Shionogi’s Mulpleo (lusutrombopag) for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) undergoing planned invasive procedures.

The decision was based on evidence indicating that the therapy met all primary endpoints in two trials of 312 CLD patients with severe thrombocytopenia and a platelet count of <50,000/µL.

Gilead's CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma

News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor T cell (CAR-T) therapy Yescarta (axicabtagene ciloleucel) on the NHS in Scotland.

Scotland approves first-line NHS use of MSD's Keytruda combo for advanced non-small cell lung cancer

The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy on the NHS in Scotland for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients.

The decision affects patients whose tumours express PD-L1 with a <50% tumour proportion score (TPS), or in when it has not been possible to evaluate PD-L1 TPS, but excludes patients whose tumours have the specific gene mutations EGFR or ALK.

Scottish NHS patients to access Pfizer's Ibrance combo in HR+/HER- breast cancer following SMC recommendation

Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after the Scottish Medicines Consortium chose to recommend the therapy in combination with fulvestrant for the treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in patients who have received prior endocrine treatment.

The decision was based on Phase 3 data supporting the efficacy of the combo therapy in the recommended indication; it is thought that ar

MSD's Keytruda recommended on NHS in Scotland for Stage 3 melanoma

MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) decided to recommend the drug’s use as a monotherapy in the treatment of Stage 3 melanoma with lymph node involvement in adult patients who have undergone complete resection.

Thanks to the decision, access to the drug in this indication is now harmonised across the Great British mainland, following a recommendation from NICE in December 2018 to make the immunotherapy available on the NHS in England and Wales.

Eisai and MSD's Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer

Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s Lenvima (lenvatinib) as a monotherapy via NHS Scotland, following a recommendation for the drug from the Scottish Medicines Consortium (SMC), it has emerged.

The SMC’s decision was made on the basis of Phase 3 data that illustrated Lenvima as non-inferior to standard of care sorafenib in improving overall survival.

Rare lung cancer drug approved in Scotland

Image Credit: Yale Rosen

The Scottish Medicines Consortium has approved Roche’s cancer drug alectinib for the treatment of patients with untreated advanced non-small-cell lung cancer (NSCLC) whose tumours are identified as ALK-positive.

The drug has been shown to improve outcomes in comparison to current standards of care. The treatment proved to reduce the risk of disease progression and death by 53% and was shown to reduce the risk of tumours in the central nervous system (CNS) by 84%.

SMC reverses decision on Opdivo in advanced skin cancer

The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended the drugs to treat Scottish NHS patients with advanced skin cancer.

Scottish regulators back BMS’ Opdivo for lung cancer

Bristol-Myers Squibb (NYSE: BMY) said the Scottish Medicines Consortium (SMC) has recommended cancer immunotherapy Opdivo (nivolumab) to treat advanced squamous non-small cell lung cancer (NSCLC). 

The drug is currently being assessed by National Institute for Health and Care Excellence (Nice). Opdivo also remains unavailable in Wales and Northern Ireland. 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches